We are live on ! Find out more
ANIK icon

Anika Therapeutics
ANIK

146 hedge funds and large institutions have $542M invested in Anika Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 53 increasing their positions, 48 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,634% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $762K

10% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 48

2.33% less ownership

Funds ownership: 95.22% → 92.89% (-2.3%)

11% less funds holding

Funds holding: 164 → 146 (-18)

12% less capital invested

Capital invested by funds: $613M → $542M (-$70.7M)

52% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 33

Holders
146
Holders Change
-18
Holders Change %
-10.98%
% of All Funds
2.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
53
Reduced
48
Closed
33
Calls
$20.8M
Puts
$762K
Net Calls
+$20.1M
Net Calls Change
-$2.13M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$21.1M
2
FWIA
Fort Washington Investment Advisors
Ohio
+$9.71M
3
State Street
State Street
Massachusetts
+$4.57M
4
BlackRock
BlackRock
New York
+$4.13M
5
Millennium Management
Millennium Management
New York
+$3.76M

Top Sellers

1
APM
Avidity Partners Management
Texas
-$33.1M
2
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management
California
-$12.3M
3
Wells Fargo
Wells Fargo
California
-$7.06M
4
PGM
Parian Global Management
New York
-$4.65M
5
ZDA
Zweig-DiMenna Associates
New York
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
176
IFP Advisors
Florida
– -$1.4K -37 Closed
CC
177
Cypress Capital
Tennessee
– +$266 +7 New
4 5 6 7
8

ANIK Hedge Fund Activity: Q1 2021 in Review

146 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2021, worth a combined $542M — down 12% from $613M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of ANIK and 16 opened new positions — a net loss of 17 holders — while 48 trimmed existing stakes and 53 added.

The largest buyer was Morgan Stanley, adding an estimated $21.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $33.1M sold.

  • 146 institutional investors held Anika Therapeutics (ANIK) as of Q1 2021, down from 164 in Q4 2020.
  • Funds reported $542M of Anika Therapeutics stock for Q1 2021, down 12% quarter-over-quarter.
  • 16 funds opened new Anika Therapeutics positions in Q1 2021 and 33 closed out, a net change of -17 holders.
  • The largest Anika Therapeutics buyer in Q1 2021 was Morgan Stanley, an estimated $21.1M added.
  • The largest Anika Therapeutics seller in Q1 2021 was Avidity Partners Management, an estimated $33.1M sold.

Based on aggregated 13F filings for Q1 2021.